Tanuja Chitnis, M.D.
Affiliations: | Neurology | Harvard Medical School and Brigham and Women Hospital, Boston, MA, United States |
Area:
Multiple Sclerosis, Pediatric Multiple Sclerosis, Natural HistoryWebsite:
https://connects.catalyst.harvard.edu/profiles/profile/person/36152Google:
"Tanuja Chitnis"Cross-listing: Neurotree
Parents
Sign in to add mentor| Samia Joseph Khoury | post-doc | Harvard Medical School and Brigham and Women Hospital (Neurotree) |
Children
Sign in to add trainee| Taha Gholipour | post-doc | 2010-2013 | Harvard Medical School and Brigham and Women Hospital (Neurotree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chitnis T, Qureshi F, Gehman VM, et al. (2024) Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis. Nature Communications. 15: 4297 |
| Airas L, Bermel RA, Chitnis T, et al. (2024) A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis. Therapeutic Advances in Neurological Disorders. 17: 17562864241233041 |
| Singhal T, Cicero S, Rissanen E, et al. (2024) Glial Activity Load on PET Reveals Persistent "Smoldering" Inflammation in MS Despite Disease-Modifying Treatment: 18F-PBR06 Study. Clinical Nuclear Medicine |
| Ziaei A, Solomon O, Casper TC, et al. (2024) Gene-environment interactions: Epstein-Barr virus infection and risk of pediatric-onset multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585231224685 |
| Ontaneda D, Chitnis T, Rammohan K, et al. (2023) Identification and management of subclinical disease activity in early multiple sclerosis: a review. Journal of Neurology |
| Bose G, Healy BC, Saxena S, et al. (2023) Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity. Neurology(R) Neuroimmunology & Neuroinflammation. 10 |
| Chitnis T. (2023) Navigating the challenges of diagnosing multiple sclerosis. The Lancet. Neurology. 22: 649-651 |
| Chitnis T, Qureshi F, Gehman VM, et al. (2023) Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect disease activity in multiple sclerosis. Medrxiv : the Preprint Server For Health Sciences |
| Malani Shukla N, Casper TC, Ness J, et al. (2023) Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments. Pediatric Neurology. 145: 125-131 |
| Hobart J, Chitnis T, Oh J, et al. (2023) Do clinical trials prepare to fail by failing to prepare? An examination of MS trials and recommendations for patient-reported outcome measure selection. Multiple Sclerosis and Related Disorders. 76: 104788 |